San Francisco-based medical genetics firm Invitae has purchased artificial intelligence software company Diploid for about $95 million.

Leuven, Belgium-based Diploid has developed an AI software called Moon, which seeks to diagnose rare diseases based on next-generation sequencing data and patient information. The purchase price consists of $32 million in cash and $63 million in common stock.

A team of Pillsbury San Diego partners Mike Hird, Richard Blaylock, Gabriella Lombardi, Peter Elias and associates Dusty Wolverton, Margaret Beale-Wirsing, Julie Park and Charmaine Lindley advised Invitae on the Diploid acquisition.